Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

11.01USD
16 Feb 2018
Change (% chg)

$0.12 (+1.10%)
Prev Close
$10.89
Open
$10.87
Day's High
$11.21
Day's Low
$10.85
Volume
267,018
Avg. Vol
245,168
52-wk High
$27.07
52-wk Low
$10.53

Chart for

About

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria... (more)

Overall

Beta: 3.49
Market Cap(Mil.): $528.52
Shares Outstanding(Mil.): 48.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721

* EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY

Jan 22 2018

BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

Jan 03 2018

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS

Dec 12 2017

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results

Nov 09 2017

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

Oct 26 2017

BRIEF-Omeros Corp amends term loan agreement

* On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​

Oct 17 2017

BRIEF-OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

* OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

Oct 05 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $133.15 +1.92
Novartis AG (NOVN.S) CHF79.68 -1.12
Pfizer Inc. (PFE.N) $36.26 +0.55
Roche Holding Ltd. (ROG.S) CHF223.15 -2.35
Roche Holding Ltd. (RO.S) CHF226.00 -4.20
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Bayer AG (BAYGn.DE) €97.78 -0.76
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.30 --
Eli Lilly and Co (LLY.N) $78.97 +0.95

Earnings vs. Estimates